China’s Rise in Drug Development Looms Over U.S.
At this year’s American Society of Clinical Oncology (ASCO) meeting in Chicago, a clinical trial conducted solely in China was featured as one of five headliners, underscoring China’s rapid ascent in biotech. Over the past few years, China’s biotech sector has shifted from a modest player to a major source of innovative oncology drugs. U.S. officials, executives, and physicians warn that the shift could erode America’s historic lead in drug discovery and jeopardize control over new therapies. The development signals a strategic inflection point for global pharmaceutical competition.
Pembrolizumab Combination Therapy Improves Survival in Recurrent Endometrial Cancer Patients
The phase 3 NRG‑GY018 trial presented at ASCO 2026 confirms that adding pembrolizumab to carboplatin‑paclitaxel extends overall survival in advanced or recurrent endometrial cancer. In the mismatch‑repair‑deficient (dMMR) cohort, 48‑month survival rose to 79% versus 60% with chemotherapy alone (HR 0.56). In...
Busy June at FDA with 11 Upcoming PDUFA Dates
The FDA has a packed June agenda with 11 PDUFA decision dates, covering at least eight new drug approvals and three new indication expansions. Among the high‑profile reviews is Ionis Pharmaceuticals’ antisense therapy Tryngolza, currently approved for familial chylomicronemia syndrome....
Teclistamab Extends Remission in Relapsed Myeloma, with 70% Progression-Free at 18 Months
A Phase III MajesTEC‑9 trial of the bispecific antibody teclistamab showed that 70% of relapsed multiple myeloma patients remained progression‑free after 18 months, far outpacing the 27% rate for standard therapies. Nearly two‑thirds of participants achieved complete remission, many reaching MRD‑negative status....
At ASCO, Merck Makes Case for a ‘Cornerstone’ Cancer Drug
Merck is positioning sacituzumab tirumotecan (sac‑TMT), an ADC discovered by China’s Kelun‑Biotech, as a potential cornerstone therapy as its blockbuster Keytruda nears patent expiry. The drug entered a 17‑study Phase 3 program and showed a 65% reduction in disease progression or...
Linvoseltamab Data ‘Encouraging’ in Relapsed AL Amyloidosis
Regeneron's bispecific antibody linvoseltamab showed rapid and deep activity in a phase 1/2 trial for relapsed or refractory systemic AL amyloidosis, with all 20 patients achieving an objective response and 90% attaining a hematologic complete response. The safety profile was manageable,...
Depemokimab Reduces Exacerbations in Type 2 Asthma, CRSwNP Over 2 Years
Depemokimab, GSK's ultra‑long‑acting biologic, achieved a 51% overall reduction in asthma exacerbations and a 69% reduction in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the phase 3 SWIFT‑1/2 trials. The drug was administered subcutaneously at 100 mg every 26 weeks, with...
Resmetirom Cuts CV Risk in MASH: Meena Bansal, MD
Resmetirom, a thyroid hormone receptor‑β agonist, showed in secondary analyses of the phase 3 MAESTRO‑NASH and MAESTRO‑NAFLD‑1 trials that it reduces LDL‑C, apolipoprotein B and lipoprotein(a) in patients with metabolic dysfunction‑associated steatohepatitis (MASH) even when they are already receiving statins. The lipid...
Pfizer, Innovent Ink Up-to-$10.5B+ Cancer Treatment Collaboration
Pfizer and China’s Innovent Biologics have signed a global licensing and collaboration deal to co‑develop and co‑commercialize 12 early‑stage antibodies and antibody‑drug conjugates (ADCs) targeting cancer. Pfizer will pay Innovent $650 million upfront and up to $9.85 billion in milestone payments, plus...
RNA Therapy for Genetic Heart Failure Moves Closer to Patients After Lab Gains
Researchers at University Medical Center Groningen demonstrated that RNA therapy targeting the PLN R14del mutation reduces protein aggregation and restores cellular function in patient‑derived heart cells. Using induced pluripotent stem cell‑derived cardiomyocytes, the treatment reversed phosphoproteomic abnormalities linked to calcium regulation....
Controversial Oncology Drug Gets Third Review From FDA
Replimune has resubmitted its oncology therapy RP1 for a third FDA review, hoping new agency leadership will overturn the earlier rejection. The drug, which targets a novel tumor antigen, was previously declined under former commissioner Marty Makary and deputy Vinay...
New Approach Methodologies (NAMs)
The FDA announced that it has achieved its Year 1 objectives for New Approach Methodologies (NAMs), dramatically reducing reliance on animal testing in drug development. By focusing first on monoclonal antibodies, the agency outlined a step‑wise roadmap that validates AI‑driven models,...
ASCO: BMS Hails "Compelling" Phase 3 Celmod Readout
Bristol Myers Squibb presented phase 3 data for mezigdomide, a cereblon E3 ligase modulator, combined with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. The SUCCESSOR‑2 trial showed a 52% reduction in progression or death risk and a median progression‑free survival of...
Can AI Crack Pharma’s Drug Repurposing Goldmine?
The FDA has opened a public comment period, ending June 11, to gather ideas on how to accelerate drug repurposing using existing therapies. It aims to identify candidates that already meet evidence standards or show early efficacy, reducing the need for...
Longevity Science Picks up Steam in Pharma
Longevity science is moving from fringe research into mainstream drug development, with Life Biosciences' ER‑100 becoming the first epigenetic reprogramming therapy to enter human trials. Retro Biosciences and Lysoway Therapeutics have also advanced neurodegeneration candidates into Phase 1, targeting autophagy pathways....
Targeted Therapy Shows Superior Results Over Chemotherapy in Treating Difficult Lung Cancer, ASCO Reports
At the American Society of Clinical Oncology (ASCO) meeting, researchers presented data showing a novel targeted therapy outperformed standard chemotherapy in patients with advanced non‑small cell lung cancer (NSCLC) that are difficult to treat. The trial reported a median progression‑free...
Can WEE1 Inhibitors Finally Make Replication Stress Druggable?
Targeting replication stress through WEE1 inhibition is re‑emerging after early setbacks. First‑generation inhibitor adavosertib demonstrated tumor responses in ovarian and uterine cancers but was limited by dose‑limiting toxicity. Newer agents such as APR‑1051, azenosertib and zedoresertib are being tested in...
Innovative Antibiotic Design Offers Hope Against Drug-Resistant Infections
Researchers at King’s College London have created an “Efflux Resistance Breaker” (ERB) that chemically modifies antibiotics to evade bacterial efflux pumps. The redesign lets drugs stay inside bacterial cells, restoring potency against multidrug‑resistant strains such as Pseudomonas aeruginosa and Klebsiella...
GSK’s Nucala Secures NICE COPD Endorsement
NICE has added GSK’s Nucala (mepolizumab) to its list of approved biologic add‑on treatments for chronic obstructive pulmonary disease (COPD) in patients with elevated eosinophils. The endorsement is based on three Phase III trials that demonstrated up to a 21 % reduction...
Pancreatic Cancer Halted by Virus Injection in Three Patients
In a U.S. Phase 1 safety trial, an engineered oncolytic virus halted tumor growth and prevented spread in three pancreatic cancer patients. Researchers administered only one‑tenth of the intended therapeutic dose, yet observed clear disease control. Lead developer Masato Yamamoto highlighted...
Samsung Bioepis Reports the EC Launch of Opuviz (Biosimilar, Eylea)
Samsung Bioepis announced the European commercial launch of Opuviz 40 mg/mL solution for injection, a biosimilar to aflibercept (Eylea). The product will be sold directly by the company across the EU for wet age‑related macular degeneration, diabetic macular oedema, retinal vein...
AstraZeneca Receives the US FDA Approval for Imfinzi Regimen to Treat High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
AstraZeneca’s Imfinzi (durvalumab) combined with Bacillus Calmette‑Guérin (BCG) therapy received U.S. FDA approval for treating adults with BCG‑naïve, high‑risk non‑muscle‑invasive bladder cancer (NMIBC). The decision rests on the phase‑III POTOMAC trial, which enrolled 1,018 patients post‑TURBT and compared Imfinzi + BCG induction...
![[Comment] Prasinezumab: What Have We Learned From PASADENA and PADOVA?](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/f31e0b4ec0510b45a35ec13b633c65e2.webp)
[Comment] Prasinezumab: What Have We Learned From PASADENA and PADOVA?
Prasinezumab, an antibody targeting aggregated α‑synuclein, was tested in the phase‑2 PASADENA trial in early‑stage Parkinson's patients. The study failed to meet its primary endpoint—change in the combined MDS‑UPDRS I‑III score after 52 weeks—though the low‑dose arm showed modest improvement...
![[Comment] Multi-Arm Multi-Stage Platform Trials for Neurological Disease: Accelerating Progress](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/c5e0887cefc9d7a6210ea0a37fc55823.webp)
[Comment] Multi-Arm Multi-Stage Platform Trials for Neurological Disease: Accelerating Progress
The Lancet commentary highlights multi‑arm multi‑stage (MAMS) platform trials as a solution to the sluggish pace of neurodegenerative drug development. By testing several mechanistically‑selected candidates within a single adaptive protocol, researchers can reach definitive phase‑3 conclusions faster. The piece cites...
This Biotech Is Leading What Could Be a 'GLP-1 Moment for Hair Loss,' Says BTIG
Absci Corporation’s AI‑designed antibody ABS‑201 is entering Phase 1/2A trials for androgenetic alopecia, a market of roughly 80 million Americans. BTIG upgraded coverage to a buy with a $9 price target, forecasting up to $2.2 billion in peak sales and likening the drug...
AbbVie’s ADC Strategy Notches Another Win With FDA Approval in Ultra-Rare Blood Cancer
AbbVie secured FDA approval for Decnupaz (pivekimab sunirine), an antibody‑drug conjugate that targets CD123 in blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra‑rare aggressive blood cancer. In a Phase 1/2 trial, 69.7% of treatment‑naïve patients achieved complete or clinical remission, while...
Vaccine Shows Promise Against Aggressive Brain Cancer
A phase‑1 trial of Geneos Therapeutics' DNA‑based vaccine GNOS‑PV01 at Washington University’s Siteman Cancer Center demonstrated safety and a survival advantage in patients with aggressive glioblastoma. The personalized vaccine, which encodes up to 40 tumor‑specific neoantigens, showed no serious adverse...
Long-Term Real-World Economic and Clinical Outcomes of TRIKAFTA® (Elexacaftor/Tezacaftor/Ivacaftor and Ivacaftor) in Cystic Fibrosis
Vertex Pharmaceuticals released a real‑world analysis of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) showing sustained clinical benefits for cystic fibrosis patients over five years. The study documented a 45% drop in annual hospitalizations, an average 8.2‑point rise in FEV1, and a net...
FDA Approves Durvalumab in Combination with Bacillus Calmette-Guerin for High-Risk Non-Muscle Invasive Bladder Cancer
The FDA approved durvalumab (Imfinzi) in combination with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The decision follows the POTOMAC trial, which enrolled 1,018 patients and demonstrated a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015)....
Bring on the Breakthroughs: ASCO Takes Translation to More Patients
The 2026 American Society of Clinical Oncology (ASCO) meeting in Chicago spotlights the theme “The Science and Practice of Translation,” showcasing data that move laboratory breakthroughs into everyday cancer care. Highlighted trials include PROTEUS, a phase‑3 study adding apalutimide to...
Tailoring Strategies to APAC’s Diverse Clinical Trial Environment
APAC is emerging as a strategic hub for clinical trials, but its regulatory, operational, and cultural diversity requires tailored sponsor strategies. Countries such as Australia and New Zealand offer streamlined early‑phase pathways, while China and India deliver large patient pools for...
Pevifoscorvir Shows Strong HBV Activity, Durable Antigen Suppression
Pevifoscorvir (ALG‑001075), a capsid assembly modulator, demonstrated nanomolar potency that far exceeds competing CAMs and earned FDA Fast Track status. Phase 1 data showed a 96‑week monotherapy course reduced HBsAg by over one log, with the decline persisting through a 24‑week...
Quantum Chemistry for Drug Discovery Still Hasn’t Had Its “ChatGPT Moment,” Biotech Founder Says
At Toronto Tech Week’s Creative Destruction Lab session, ProteinQure co‑founder Mark Fingerhuth warned that quantum chemistry has yet to experience a “ChatGPT moment” in drug discovery. While Xanadu’s CEO touted quantum chemistry as low‑hanging fruit, Fingerhuth argued that the real...
‘Excitement and Interest’ as Lp(a) Therapies Inch Closer
Late‑phase trials of dedicated lipoprotein(a) therapies are nearing completion, with the phase 3 Lp(a)HORIZON trial of pelacarsen slated for readout in the second half of 2026. Multiple modalities—including antisense oligonucleotides, siRNA agents, oral small‑molecule inhibitors, CETP inhibitors, and gene‑editing platforms—have demonstrated...
DD01, Pemvidutide Data Suggest Dual Agonists Target MASH Directly: Mazen Nourredin, MD
Phase‑2 trials of the dual GLP‑1/glucagon agonists DD01 and pemvidutide revealed significant reductions in liver‑fat content and stiffness in patients with metabolic dysfunction‑associated steatohepatitis (MASH). DD01 achieved a 30% MRI‑PDFF reduction in 76% of participants by week 12, even though average...
FDA Oncology Roundup: AbbVie’s Rare Cancer Approval, AstraZeneca in Breast Cancer Limbo
The FDA approved AbbVie’s CD123‑targeting antibody‑drug conjugate Decnupaz for blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra‑rare aggressive blood cancer, after the CADENZA trial reported a 69.7% composite complete response in newly diagnosed patients and 15.7% in relapsed/refractory cases. The...
Biohub Open-Source AI Model Targets Protein Design for Drug Discovery
Biohub, part of the Chan Zuckerberg Initiative, launched an open‑source AI system that models protein biology at evolutionary scale to aid early‑stage drug discovery. The platform, described as a “world model,” was used to design protein binders targeting cancer and...
A One-Time Experimental Treatment Might Control Cholesterol for Life
Verve Therapeutics, an Eli Lilly subsidiary, reported early‑stage results for its one‑time gene therapy VERVE‑102, which edits the PCSK9 gene in liver cells. In a dose‑escalation study of 35 participants, LDL cholesterol fell between 9% and 62% after a single infusion,...
Is Immune Priming the Missing Piece in Oncology? Oncolytics Biotech Thinks So
Oncolytics Biotech is positioning its oncolytic virus pelareorep as an "immune‑priming backbone" to boost the efficacy of existing cancer therapies. Recent combination trials have shown striking survival gains—median overall survival of 27 months in metastatic colorectal cancer and a two‑year...
Open Source Therapeutics Divulges New PARP-1 Inhibitors
Open Source Therapeutics announced the discovery of two first‑in‑class PARP‑1 inhibitors aimed at treating DNA‑repair‑deficient cancers. The compounds demonstrated up to 80% tumor growth inhibition in mouse xenograft models and exhibit oral bioavailability with a half‑life suitable for once‑daily dosing....
Traws Pharma Announces New Antiviral Program
Traws Pharma announced a new antiviral development program aimed at emerging RNA viruses and other high‑risk pathogens. The initiative earmarks roughly $200 million over the next five years to fund pre‑clinical research, platform technology, and early‑stage clinical trials. The company is...
Use of Ultra-Rapid Insulin Plus MiniMed 780G Raises Time in Range
A single‑arm trial of 211 participants with type 1 diabetes showed that pairing Eli Lilly’s ultra‑rapid insulin lispro‑aabc (Lyumjev) with Medtronic’s MiniMed 780G hybrid closed‑loop system significantly boosted time‑in‑range. Children achieved a mean TIR of 68.6% (up from 51.2%) and adults reached...
Vertex’s Journavx Made History, but Left a Void in the Pain Space
Vertex Pharmaceuticals secured FDA approval for Journavx, the first novel non‑opioid pain drug in decades, amid the ongoing opioid crisis and Purdue Pharma’s recent multi‑billion‑dollar settlement. The medication targets the NaV1.8 sodium channel and quickly reached one million prescriptions, but...
Ironwood Pharmaceuticals Reports the US FDA Approval of Linzess to Treat Pediatric Patients (≥2yrs.) With Functional Constipation
U.S. FDA has approved an expanded label for Ironwood Pharmaceuticals’ Linzess (linaclotide) for children aged two years and older with functional constipation. The decision follows a 12‑week Phase III trial in 2‑ to 5‑year‑old patients, where the 72 µg dose significantly increased...
Apogee Therapeutics Reports Part B P-II (APEX) Data on Zumilokibart in Atopic Dermatitis (AD)
Apogee Therapeutics announced Phase II Part B (APEX) results for its IL‑4/13 inhibitor zumilokibart in moderate‑to‑severe atopic dermatitis. In a 346‑patient study, the mid‑ and high‑dose arms met the primary endpoint at week 16, with 65.9% and 61.6% of patients achieving EASI‑75 versus...
STAT+: Trump’s Drug-Pricing Deals Set to Be Tested by New Product Launches
President Trump’s most‑favored‑nation (MFN) agreements with 17 drugmakers require new U.S. launches to be priced at net levels comparable to other wealthy nations. The policy, whose terms remain secret, is slated for its first public test as three drugs—AstraZeneca’s hypertension...
Sanofi’s Venglustat Secures the US FDA Priority Review for Type 3 Gaucher Disease
Sanofi’s oral glucosylceramide synthase inhibitor venglustat has received FDA acceptance of its New Drug Application and a priority‑review designation for treating the neurological manifestations of type 3 Gaucher disease (GD3). The decision follows the phase‑III LEAP2MONO trial, which enrolled 43 patients...
AbbVie Reports the US FDA Approval for Decnupaz to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
AbbVie’s Decnupaz (pivekimab sunirine‑pvzy) received U.S. FDA approval for treating adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra‑rare aggressive blood cancer. The decision was based on the global Phase I/II CADENZA trial that enrolled 84 CD123‑positive hematologic malignancy...
New Drug ‘Functionally Cures’ Many Hepatitis B Virus Infections
GSK’s antisense drug bepirovirsen (bepi) added to standard antivirals produced a functional cure in 19% of chronic hepatitis B patients in two phase 3 trials, rising to 26% among those with the lowest surface‑antigen levels. The cure, defined as undetectable HBV DNA...
Merck and Mastercard Are Seeing Real Agentic AI Results. Both Say the Plumbing Came First.
Merck is leveraging AI agents to accelerate drug discovery and marketing, cutting research cycles by a third and delivering compliant marketing drafts up to 80% faster. The gains stem from a "plumbing‑first" strategy that now supports 2,500 AWS accounts, multiple...